<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04310215</url>
  </required_header>
  <id_info>
    <org_study_id>CARTISTEM_2019_01</org_study_id>
    <nct_id>NCT04310215</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Allogenic Stem Cell Product(CARTISTEM®) for Osteochondral Lesion of Talus</brief_title>
  <official_title>A Multi-center, Single-blind, Randomized, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Adding CARTISTEM® on Microfracture in Patients With Talar Chondral or Osteochondral Defect</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hyundai Bioland Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medipost Co Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hyundai Bioland Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of adding&#xD;
      CARTISTEM®(allogenic umbilical cord blood-derived stem cell product) on microfracture, a&#xD;
      currently standard treatment for OLT, in patients with talar chondral or osteochondral&#xD;
      defect.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 3, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A multicenter, Single-blinded, Stratified randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ICRS-Cartilage Repair Assessment Total Score</measure>
    <time_frame>Week 48</time_frame>
    <description>Arthroscopic evaluation of articular cartilage repair&#xD;
: The score range from 12(normal) to 1(severely abnormal) where lower scores indicate more severity of injury</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICRS-Cartilage Repair Assessment Overall Grade</measure>
    <time_frame>Week 48</time_frame>
    <description>The grades range from 1(normal) to 4 (severely abnormal) where lower grades indicate more complete repair</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement degree of Cartilage Repair by MRI</measure>
    <time_frame>Week 0 and 48</time_frame>
    <description>Changes in MOCART(Magnetic resonance Observation of Cartilage Repair Tissue) score&#xD;
: MOCART score is a 9-part and 29-item scoring system, also resulting in a find cartilage repair tissue score between 0 and 100 points. 100 points represent the best imaginable score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of Functional improvement in FAOS(Foot &amp; Ankle Outcome Score)</measure>
    <time_frame>Week 0, 24 and 48</time_frame>
    <description>: FAOS consists in 42 items that cover 5 dimensions (symptoms, pain, activities of daily living, sport and recreation activities, and quality of life. Raw scores of each sub-scales results of the sum of each items. A normalized score (100 indicationg no symptoms and 0 indicating extreame sysmptoms) is calculated for each subscale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of Functional improvement in AOFAS(The American Orthopaedic Foot &amp; Ankle Score)</measure>
    <time_frame>Week 0, 24 and 48</time_frame>
    <description>: AOFAS consists in 9 items that can be divided into 3 sub-scales (pain, function and alignment). 100 points of 1 to 100 represent no symptoms or impairments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of Functional improvement in Tegner activity score</measure>
    <time_frame>Week 0, 24 and 48</time_frame>
    <description>: Tegner activity represents the highest level of activity on scale of 0 to 10 that you are able to participate in currently . The higher values represent a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of Quality of Life improvement in SF-36(Short Form Health Survey-36)</measure>
    <time_frame>Week 0, 24 and 48</time_frame>
    <description>: SF-36 comprises 36 items divided into two components of physical health and mental health. Higher scores between 0 and 100 represent better health status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of pain improvement in 100 mm VAS(Visual Analogue Scale)</measure>
    <time_frame>Week 0, 24 and 48</time_frame>
    <description>VAS represents higher scores mean higher pain&#xD;
0 mm (no pain) and 100 mm (worst pain)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Chondral or Osteochondral Lesion of Talus</condition>
  <arm_group>
    <arm_group_label>Microfracture + CARTISTEM®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CARTISTEM® is added on the lesion as a single dose of 500 ㎕/㎠ according to the defect size after arthroscopic curettage and microfracture.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microfracture</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment of arthroscopic curettage and microfracture is performed for cartilage defect.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CARTISTEM®</intervention_name>
    <description>*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠&#xD;
Procedure: Microfracture&#xD;
Biological: CARTISTEM®(Human Umbilical Cord Blood-derived Mesenchymal Stem Cell product)</description>
    <arm_group_label>Microfracture + CARTISTEM®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Microfracture</intervention_name>
    <description>*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠&#xD;
1. Procedure: Microfracture</description>
    <arm_group_label>Microfracture</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Talar chondral/osteochondral lesion confirmed by radiographical exam at screening or&#xD;
             diagnosis, an AOFAS score of 75 or below&#xD;
&#xD;
          2. Ankle joint pain/stiffness with no response to conservative treatment for more than 12&#xD;
             weeks&#xD;
&#xD;
          3. Ankle joint cartilage injury of defect of ICRS grade Ⅳ&#xD;
&#xD;
          4. Male or female aged more than 18&#xD;
&#xD;
          5. A one-sided lesion&#xD;
&#xD;
          6. Appropriate function of blood clot: PT(INR) &lt; 1.5×ULN, aPTT &lt;1.5×ULN&#xD;
&#xD;
          7. Appropriate renal function: Creatinine ≤ 2.0 ㎎/㎗, Proteinuria ≤ trace&#xD;
&#xD;
          8. Appropriate hepatic function: Total bilirubin ≤ 2.0 ㎎/㎗, AST/ALT ≤ 100 IU/L&#xD;
&#xD;
          9. No evidence of auto-immune disorder: According to investigator's judgement based on&#xD;
             relevent symtom and physical exam, anti-nuclear antibody and anti-thyroglobulin&#xD;
             antibody tests are able to performed and confirmed negative (If positive, there are&#xD;
             possible cases according to diagnostic opinion of medical department)&#xD;
&#xD;
         10. No surgery or radiotherapy for the same ankle joint within 6 weeks&#xD;
&#xD;
         11. Female patients agreeing with maintenance of contraception* during study period&#xD;
&#xD;
             *hormone contraceptive, implants of intrauterine device or intrauterine system, double&#xD;
             barrier contraception[Concurrent use of diaphragm or cervical occlusive cap and male&#xD;
             condom], surgical sterilisation, etc.&#xD;
&#xD;
         12. No chronic ligament instability more than grade Ⅲ (Grade 0: none, Grade Ⅰ: 1~5㎜,&#xD;
             GradeⅡ: 5~10㎜, Grade Ⅲ: &gt;10㎜)&#xD;
&#xD;
         13. Patients agreeing with participation in this study and signed on informed consent by&#xD;
             their own will&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Degenerative arthritis in ankle(Kellgren Lawrence Grade 3-4)&#xD;
&#xD;
          2. Autoimmune disease&#xD;
&#xD;
          3. Infectious disease need to administration of parenteral antibiotics&#xD;
&#xD;
          4. Myocardial infarction, congestive heart failure, other serious cardiac disorder or&#xD;
             uncontrolled resistant hypertension&#xD;
&#xD;
          5. Serious medical disease(Ex. Kidney disease such as chronic renal failure or&#xD;
             Glomerulonephritis, etc., acute/chronic liver disease such as liver cirrhosis, fatty&#xD;
             liver etc., medical history of malignancy*)&#xD;
&#xD;
             *Complete remission status is possible.&#xD;
&#xD;
          6. Pregnancy or breast-feeding&#xD;
&#xD;
          7. Psychiatric history or epilepsy&#xD;
&#xD;
          8. Alcohol abuse&#xD;
&#xD;
          9. Heavy smoker&#xD;
&#xD;
         10. Chronic inflammatory disease such as rheumatoid arthritis&#xD;
&#xD;
         11. Participants other clinical trials within 4 weeks&#xD;
&#xD;
         12. Administration of immunosuppressing agents such as Cyclosporin A or azathioprine&#xD;
             within 6 weeks&#xD;
&#xD;
         13. Patients with acute ligament injury and clinically significant chronic ligament&#xD;
             instability&#xD;
&#xD;
         14. Patients treated with surgery or cell therapy product for the same disease&#xD;
&#xD;
         15. Patients with hypersensitivity or allergy history to bovine protein, hyaluronic acid&#xD;
             and gentamicin&#xD;
&#xD;
         16. Other inappropriate patients determined by the principal investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kyunghee University Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Dongdaemun-gu</state>
        <zip>02447</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Gangnam-gu</state>
        <zip>06273</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Gangnam-gu</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Guro-gu</state>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <state>Jung-gu</state>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <state>Jung-gu</state>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 12, 2020</study_first_submitted>
  <study_first_submitted_qc>March 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2020</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OLT</keyword>
  <keyword>Talus</keyword>
  <keyword>Chondral Lesion</keyword>
  <keyword>Osteochondral Lesion</keyword>
  <keyword>Human umbilical cord blood-derived stem cell</keyword>
  <keyword>MSC</keyword>
  <keyword>Mesenchymal stem cell</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be shared to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

